Evidence map›Paper›PMID 27825338›Full record

ArticleBMC biotechnology2016

Sequential and counter-selectable cassettes for fission yeast.

Hanna Amelina, Vera Moiseeva, Laura Catharine Collopy, Siân Rosanna Pearson, Christine Anne Armstrong, Kazunori Tomita

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Overexpression ofMicroorganisms · 2019
    Article
  9. Article
  10. Article
  11. New Plasmids forFrontiers in microbiology · 2018
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hanna AmelinaChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.
Vera MoiseevaChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.
Laura Catharine CollopyChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.
Siân Rosanna PearsonChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.
Christine Anne ArmstrongChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.
Kazunori TomitaChromosome Maintenance Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK. k.tomita@ucl.ac.uk.ORCID http://orcid.org/0000-0003-1096-6725
CRUK Lung Cancer Centre of Excellence · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFission yeast is one of the most commonly used model organisms for studying genetics. For selection of desirable genotypes, antibiotic resistance cassettes are widely integrated into the genome near genes of interest. In yeasts, this is achieved by PCR amplification of the cassette flanked by short homology sequences, which can be incorporated by homology directed repair. However, the currently available cassettes all share the same tef promoter and terminator sequences. It can therefore be challenging to perform multiple genetic modifications by PCR-based targeting, as existing resistance cassettes in strains can be favored for recombination due to shared homology between the cassettes.

resultsHere we have generated new selection cassettes that do not recombine with those traditionally used. We achieved this by swapping the tef promoter and terminator sequences in the established antibiotic resistance MX6 cassette series for alternative promoters and/or terminators. The newly created selection cassettes did not recombine with the tef-containing MX6 cassettes already present in the genome, allowing for sequential gene targeting using the PCR-based method. In addition, we have generated a series of plasmids to facilitate the C-terminal tagging of genes with desired epitopes. We also utilized the anti-selection gene HSV-TK, which results in cell death in strains grown on the drug 5-Fluoro-2'-deoxyuridine (FdU, Floxuridin or FUDR). By fusing an antibiotic resistance gene to HSV-TK, we were able to select on the relevant antibiotic as well as counter-select on FdU media to confirm the desired genomic modification had been made. We noted that the efficiency of the counter selection by FdU was enhanced by treatment with hydroxyurea. However, a number of DNA replication checkpoint and homologous recombination mutants, including rad3∆, cds1∆, rad54∆ and rad55∆, exhibited sensitivity to FdU even though those strains did not carry the HSV-TK gene. To remove counter-selectable markers, we introduced the Cre-loxP irreversible recombination method. Finally, utilizing the negative selectable markers, we showed efficient induction of point mutations in an endogenous gene by a two-step transformation method.

conclusionsThe plasmid constructs and techniques described here are invaluable tools for sequential gene targeting and will simplify construction of fission yeast strains required for study.

Indexed as

DNA, FungalDrug Resistance, FungalGene TargetingMutagenesis, InsertionalPoint MutationPromoter Regions, GeneticSchizosaccharomycesDNA, FungalDNA replicationFUdRGene disruption and insertionHA, Flag, PK taggingPoint mutationSchizosaccharomyces pombeThymidine kinaseZeocin

Identifiers

PMID27825338
PMCPMC5101803
OpenAlexW2553285337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.